Notch Pathway Inhibitors DLL4

The Notch signaling pathway has been found to play central roles in humans in stem cell maintenance, cell fate decisions, and in cancer as well. Notch family members are being revealed as oncogenes...

FDA Clears OncoMed's Demcizumab (Anti-DLL4) to Resume Clinical Testing in the US

Partial Clinical Hold Removed By FDA REDWOOD CITY, Calif.--(BUSINESS WIRE)--Jan 2, 2013 - OncoMed Pharmaceuticals, a clinical-stage company developing novel therapeutics that target cancer stem cells...

FDA Clears OncoMed’s Demcizumab (Anti-DLL4) to Resume Clinical Testing in the US

Partial Clinical Hold Removed By FDA

Clinical Cancer Research Publishes OncoMed Data Demonstrating Anti-Cancer Activity for ...

Targeting DLL4-Notch Signaling Inhibits Tumor Growth and Reduces Cancer Stem Frequency in Patient-Derived Pancreatic Cancer Models

Lonza to develop OncoMed anti-cancer therapeutics

Lonza has signed an agreement with OncoMed to develop and manufacture OncoMed's pipeline of anti-cancer stem cell therapeutics.

FDA Clears OncoMed’s Demcizumab (Anti-DLL4) to Resume Clinical Testing in the US

OncoMed Pharmaceuticals, a clinical-stage company developing novel therapeutics that target cancer stem cells (CSCs), or tumor-initiating cells, today announced that the U.S. Food...

OncoMed announces data from demcizumab preclinical study on pancreatic cancer

OncoMed Pharmaceuticals, Inc., a clinical-stage company developing novel therapeutics that target cancer, today announced the online publication in Clinical Cancer Research of preclinical data demonst...

Clinical Cancer Research Publishes OncoMed Data Demonstrating Anti-Cancer Activity for Anti-DLL4 (Demcizumab) in Pancreatic Cancer

OncoMed Pharmaceuticals, Inc., a clinical-stage company developing novel therapeutics that target cancer, today announced the online publication in Clinical Cancer Research of pre...

OncoMed to Present New Data in Six Anti-Cancer Stem Cell Programs at AACR

OncoMed Pharmaceuticals, Inc., a clinical-stage company developing novel therapeutics that target cancer stem cells (CSCs), or tumor-initiating cells, today announced an oral pres...

Feed-forward Signaling by Membrane-bound Ligand Receptor Circuit: THE CASE OF NOTCH DELTA-LIKE 4 LIGAND IN ENDOTHELIAL CELLS.

The DELTA like-4 ligand (DLL4) belongs to the highly conserved NOTCH family and is specifically expressed in the endothelium. DLL4 regulates crucial processes in vascular growth, including endothelial...

Cross-talk between endothelial cells and tumor via delta-like ligand4/Notch/PTEN signaling inhibits lung cancer growth.

Lung cancer is a leading cause of cancer death in many countries. Notch signaling has been demonstrated to frequently participate in the process of lung carcinogenesis. Delta-like ligand 4 (Dll4) is a...

Endothelial basement membrane limits tip cell formation by inducing Dll4/Notch signalling in vivo.

How individual components of the vascular basement membrane influence endothelial cell behaviour remains unclear. Here we show that laminin α4 (Lama4) regulates tip cell numbers and vascular density...

Ongoing Dll4-Notch signaling is required for T-cell homeostasis in adult thymus.

The essential role of the Delta-like ligand-4 (Dll4)-Notch signaling pathway in T lymphocyte development is well established. It has been shown that specific inactivation of Dll4 on thymic stromal cel...

Ameliorating effects of anti-Dll4 mAb on Theiler's murine encephalomyelitis virus-induced demyelinating disease.

We examined the role of Notch ligand Delta-like 4 (Dll4) in the development of Theiler's murine encephalomyelitis virus (TMEV)-induced demyelinating disease (TMEV-IDD). Treatment with mAb to Dll4, esp...